On March 13, 2019, Marc Ullman will be a presenter in an EAS Consulting Group webinar entitled “What Does the 2018 Farm Bill Mean for the Cannabis Industry?” The webinar will offer an informative discussion on the FDA’s position on cannabis and how the patchwork of state regulations makes the topic confusing.

Accompanying Marc will

Marc Ullman was quoted in the Nutraingredients-USA article, “Hemp and CBD in pet supplements weaves same tangled web as in products meant for humans.” The focus of the article is the regulatory gray area for hemp and CBD in supplements intended for animals.

Ullman noted, “FDA has been very quiet in this area. CB in pet

On January 15, Marc Ullman will be speaking at the New York State Bar Association’s “Hot Topics in Cannabis Law 2019: What Lawyers Need to Know.”

He will be speaking on the topic of “CBD: What is it and What it Can Be.”

1. 0 CLE credit in the Areas of Professional Practice being offered.

Marc Ullman was interviewed for a January 2, 2019, article in Life Science Leader magazine entitled “The Unique Challenges Facing Cannabis-based Pharma.” The story covers the lengthy process to get Epidiolex, the first ever pharmaceutical derived from cannabis, approved for medical use.

Marc noted that GW Pharmaceuticals, which developed Epidiolex, was successful because it is

On December 14, Marc Ullman will be participating in the Hemp CBD Legal Roundtable at the Governor’s Office in NYC.

The roundtable will be facilitated by Axel Bernabe, Assistant Counsel to the Governor, Scott Wyner, General Counsel of the Department of Agriculture and Markets, and Brian Malkin, Co-Chair of the New York State Bar Association’s

Marc Ullman was quoted in a Natural Products Insider article, “FDA warns drug manufacturer marketing CBD products.”

According to FDA, all CBD products sold as supplements are noncompliant, said Ullman.

“But they [FDA officials] are using their discretion for now and acting only against the products making illegal drug claims,” Ullman informed. “The thing about enforcement discretion

Marc Ullman  will be a speaker at the Dietary Supplement Good Manufacturing Practices (GMP) Compliance Seminar, with a special section on applying GMP concepts to the cannabis industry. The program will take place at Hotel Indigo in Dallas, Texas in September 2018.

At the Dietary Supplement GMP Seminar, You Will:

• Receive detailed practical guidance

Marc Ullman was quoted in a NutraIngredients-USA article, “FDA says Gottlieb statement does not signal CBD enforcement shift, but some questions unanswered, observers say.”

A statement by FDA Commissioner Dr. Scott Gottlieb noted that the US Food and Drug Administration has approved the first CBD drug, which was developed by English company GW Pharmaceuticals. The

Marc Ullman was quoted in a Natural Products Insider article entitled, “CO Hemp Food Bill Passed by Legislature Seeks to Pre-Empt Pharma Lawsuits.” The article addresses a proposed bill in Colorado that will codify into law an existing policy to regulate hemp as a food ingredient.

Click here to read the article.

Marc Ullman was quoted in a Natural Products Insider article entitled, “FDA Triggered Industry Shift from ‘CBD’ to ‘Hemp Extracts’ in Dietary Supplements.” The article addresses the point that amid the escalating demands for CBD in the United States, many companies are selling “hemp extracts,” a strategy based on regulatory and scientific considerations.”

“If you’re